XENE - Company ID 0001582313
The table below shows Xenon Pharmaceuticals Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $199.16M | $142.71M | $148.64M | $57.24M | $175.69M | $45.01M |
| Short-term investments | $349.72M | $484.19M | $489.44M | $534.85M | $376.09M | $131.99M |
| Receivables | - | $1.47M | $874.00K | $986.00K | $2.77M | $1.82M |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $560.65M |
| $635.26M |
| $644.96M |
| $600.30M |
| $559.02M |
| $181.78M |
| Property, plant & equipment | $8.72M | $10.28M | $9.65M | $6.50M | $4.47M | $3.55M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $633.16M | $798.14M | $964.80M | $754.15M | $572.01M | $189.19M |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $41.79M | $35.59M | $27.27M | $22.70M | $14.32M | $14.78M |
| Long-term debt | - | - | - | - | - | $10.89M |
| Total liabilities | $51.40M | $43.24M | $36.88M | $32.65M | $21.97M | $17.83M |
| Retained earnings | -$1.25B | -$899.47M | -$665.14M | -$482.75M | -$357.37M | -$278.49M |
| Total equity | $581.76M | $754.90M | $927.92M | $721.50M | $550.03M | $171.35M |